louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04046419: In Turkish Version "Health Care Providers and Impairment Relationship Scale (HC-PAIRS)"
Official title: Turkish Validity and Reliability of "Health Care Providers and Impairment Relationship Scale (HC-PAIRS)"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Low-back Pain
Health Personnel Attitude
Keywords: validity, reliability, Turkish version, HC-PAIRS
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2019-08-06
Enrollment: 165
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study will be carried out by physiotherapists working in the KSBU Evliya Celebi Hospital or accessible via internet.

Brief summary: The aim of this study was to determine the Turkish validity and reliability of ''Health Care Providers and Impairment Relationship Scale HC (HC-PAIRS)'' developed by Dr Rainville.

Detailed description: Low back pain is one of the reasons for applying to health institutions. Low back pain, which seriously affects patients' lives and leads to major financial losses, causes serious deficiencies in both developing and developed countries. Health professionals' perception of pain, factors associated with pain and fear avoidance attitudes of patients affect the success of treatment. The aim of this study is to determine the Turkish version, validity and reliability of ''Health Care Providers and Impairment Relationship Scale (HC-PAIRS)''. 165 physiotherapist working with chronic low back pain were included in the study. In order to determine the reliability of the scale, the intraclass correlation coefficient (ICC) will be used to determine the level of the relationship between the results of the first and second measurements. Cronbach's alpha coefficient will be used for homogeneity of the questions in the scale. For concurrent validity, correlation coefficient will be used to determine the agreement between the previously validated scales and the Turkish version of HC PAIRS.

Eligibility criteria: Inclusion Criteria:

* Graduate with a bachelor's degree in physiotherapy and rehabilitation
* To have worked in patients with chronic low back pain

Exclusion Criteria:

* Not having experience in the clinic about low back pain

Primary outcomes:
measure: The Health Care Providers' Pain and Impairment Relationship Scale
timeFrame: 10 minute
measure: Turkish version of Tampa Scale for Kinesiophobia
timeFrame: 10 minute
Secondary outcomes:
measure: Pain Attitudes and Beliefs Scale for Physiotherapists (PABS-PT)
timeFrame: 10 minute.
Other outcomes:
Locations:
city: Kütahya
country: Turkey
facility: Kutahya Health Science University
Study officials:
affiliation: Kutahya Health Science University
name: Cihan C AKSOY, PhD
role: STUDY_DIRECTOR
affiliation: Kutahya Health Science University
name: İsmail SARACOGLU, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kutahya Health Science University
name: Lütfiye AKKURT, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03750019: Remembered Meal Satisfaction, Satiety and Later Snack Food Intake
Official title: Remembered Meal Satisfaction, Satiety and Later Snack Food Intake: A Laboratory Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Keywords: food intake
memory
remembered satisfaction
memory for recent eating
satiety
eating behavior
Lead sponsor: University of Liverpool
Sponsor class: OTHER
First posted: 2018-11-21
Enrollment: 146
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study examined whether remembered meal satisfaction (encompassing memory for meal liking and satiety) can be manipulated in the laboratory and whether this influences later food intake.

Detailed description: This study examined whether remembered meal satisfaction (encompassing memory for meal liking and satiety) can be manipulated in the laboratory and whether this influences later food intake. In a between-subjects design participants consumed a fixed lunch and then rehearsed the satisfying or dissatisfying aspects of the meal, or a neutral experience (control), in order to manipulate memory for meal satisfaction. Three hours later, in a second visit to the laboratory, participants completed a bogus taste-test to measure food intake and meal memory measures.

Eligibility criteria: Inclusion Criteria:

* Fluent English
* Not taking medication that affects appetite
* No known history of food allergies or disordered eating

Primary outcomes:
measure: Ad libitum snack intake
timeFrame: Measured during second visit that took place 3 hours after the baseline visit
Secondary outcomes:
measure: Memory for general satisfaction
timeFrame: Measured during second visit that took place 3 hours after the baseline visit
measure: Memory for satisfaction with meal satiety
timeFrame: Measured during second visit that took place 3 hours after the baseline visit
Other outcomes:
measure: Hunger before lunch
timeFrame: Measured before lunch (during baseline visit)
measure: Hunger after lunch
timeFrame: Measured after lunch (during baseline visit)
measure: Hunger before the bogus taste-test
timeFrame: Measured before the bogus taste-test (in second visit that took place 3 hours after the baseline visit)
measure: Hunger after the bogus taste-test
timeFrame: Measured after the bogus taste-test (in second visit that took place 3 hours after the baseline visit)
Locations:
city: Liverpool
country: United Kingdom
facility: University of Liverpool
Study officials:
affiliation: University of Liverpool
name: Eric Robinson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03830619: Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis
Official title: Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer (Diagnosis)
Keywords: exosomes；lncRNA； lung cancer；
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2019-02-05
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed as lung cancer by histopathology or cytopathology in union hospital.

Brief summary: The study is to investigate the sensitivity and specificity of serum exosome noncoding RNA as a biomarker for the diagnosis of lung cancer

Detailed description: Conventional tumor markers for non-invasive diagnosis of Lung cancer (LC) exhibit insufficient sensitivity and specificity to facilitate detection of early lung cancer (ELC). The investigators aimed to identify ELC-specific exosomal lncRNA biomarkers that are highly sensitive and stable for the non-invasive diagnosis of ELC.Hence, in the present study, exosomes from the plasma of five healthy individuals and 30 LC patients and from culture media of four human bronchial epithelial cells and four cancer cells were isolated. Exosomal RNA profiling was performed using RNA sequencing to identify LC specific exosomal lncRNAs.

Eligibility criteria: Inclusion Criteria:

* Subjects are willing to sign the informed consent form;
* Normal subjects have no evidence of any disease;
* Lung cancer patients are 18 to 75 years old, diagnosed as lung cancer by histopathology or cytopathology

Exclusion Criteria:

* People are unwilling to sign the informed consent form;
* Patients with heart disease, rheumatic disease, allergic disease, COPD, pulmonary fibrosis, diabetes, thyroid disease, liver, kidney, brain disease and hematopoietic system disease;
* Pregnant or lactating women;
* Patients did not cooperate or participate in other clinical trials

Primary outcomes:
measure: The expression levels of serum exosome long non-coding RNA
timeFrame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study
measure: the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1
timeFrame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study
measure: the CT scans of the lung for the patients
timeFrame: the first day subjects are enrolled the outcome will be assessed；up to three years after the completion of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT05025319: Optimization of Bedside Chest X-rays Taken in the Intensive Care Unit by Using Current Software-based Techniques
Official title: Optimization of Bedside Chest X-rays Taken in the Intensive Care Unit by Using Current Software-based Techniques
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: X-Rays
Keywords: Imaging
Grid
X-ray
Image quality
Lead sponsor: Joint Authority for Päijät-Häme Social and Health Care
Sponsor class: OTHER
Collaborators: name: Tampere University
First posted: 2021-08-27
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intensive care patients

Brief summary: This study investigates how to utilize an algorithm-based virtual grid in lung imaging in intensive care unit patients. The aim is to compare the radiation dose caused by imaging with a virtual grid and a traditional grid and relate this to the achieved image quality. The study aims to determine how the radiation dose can be lowered and still obtain the same diagnostic image quality as using a traditional scatter-limiting lattice.


Eligibility criteria: Inclusion Criteria:

* All patients in the intensive care unit with an imaging of the lung.

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Image quality
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Lahti
country: Finland
facility: Joint Authority for Päijät-Häme Social and Health Care
Study officials:
References:
Clinical trial NCT00496119: Proton Beam Therapy for Chordoma Patients
Official title: Phase II Evaluation of Proton Beam Therapy for Skull Base Chordoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Chordoma
Keywords: Proton Beam Therapy
Skull Base Chordoma
Chordoma of the Skull Base
Chordoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2007-07-04
Enrollment: 19
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical research study is to learn if proton beam therapy, with or without photon beam radiation therapy, is effective in the treatment of skull base chordoma. The safety of this treatment will also be studied.

Detailed description: Proton therapy is a kind of external beam radiation therapy where protons are directed to a tumor site. Researchers are trying to determine what level of proton therapy gives the most benefit without causing toxic side effects. Researchers will also be testing the treatment's effect.

If your doctor feels it is necessary, the proton beam therapy may be combined with standard photon therapy.

If you are eligible to take part in this study, you will receive proton beam therapy at The University of Texas (UT) MD Anderson Cancer Center (MDACC), and possibly photon beam, no sooner than 2 weeks after the last surgery to remove the tumor. You will receive proton beam therapy once a day for about 35 treatments (7 weeks). Treatment will be given for 5 days in a row each week (except for Saturdays, Sundays and holidays) at the MDACC Proton Center in Houston. The whole process should take up to 1 hour each day.

This is an investigational study. The proton beam machine used to deliver treatment is approved by the FDA for patient use. The doses being studied are experimental. About 15 participants will take part in this study. All will be enrolled at MDACC.

Eligibility criteria: Inclusion Criteria:

1. Pathologically confirmed chordoma of the skull base
2. Contrast enhanced postoperative MRI (CT in case MRI is contraindicated) of the skull base obtained within 90 days of study registration
3. MDACC surgeons have determined that optimal debulking of disease has been performed.
4. Karnofsky Performance status greater than or equal to 60
5. Signed informed consent

Exclusion Criteria:

1. Previous irradiation of the skull base
2. Documented evidence of disseminated metastatic disease
3. Any concurrent malignancy (other than non-melanoma skin cancers) in the last 3 years

Primary outcomes:
measure: Time to Local Recurrence
timeFrame: 1 year after radiation treatments
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: David Grosshans, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01142219: L-Arginine and Sickle Cell Disease
Official title: A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sickle Cell Disease
Keywords: sickle cell disease
L-arginine
hemolysis
nitric oxide
pulmonary arterial hypertension
Lead sponsor: Hospital de Clinicas de Porto Alegre
Sponsor class: OTHER
Collaborators: name: Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)
name: Associação de Amigos da Hematologia (HEMOAMIGOS)
name: Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine)
First posted: 2010-06-11
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: One of the main problems in sickle cell disease is the decreased bioavailability of nitric oxide and arginine. This study was designed to assess if treating sickle cell disease patients with L-arginine would improve pulmonary arterial pressure and other aspects.

Detailed description: This is a phase III, randomized, double-blind, placebo-controlled clinical trial with sickle cell disease patients older than 1 year of age. The patients were randomly assigned to take 0.1 g/kg/day of either L-arginine or placebo orally. Adverse events were monitored by a safety committee. The variables were assessed while patients were in remission, as part of their routine care: weight, blood pressure, full blood cell count, creatinine and dosage of methemoglobin at baseline and at each follow-up visit. Peripheral oxygen saturation (SpO2), fetal hemoglobin, lactate dehydrogenase and tricuspid regurgitant jet velocity were measured through transthoracic Doppler echocardiogram before and after treatment.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of sickle cell disease confirmed through hemoglobin electrophoresis
* Genotypes SS, SC and Sβ thalassemia
* Age \> 1 year

Exclusion Criteria:

* Liver dysfunction (alanine aminotransferase ALT \> 3 times the normal levels
* Renal dysfunction (creatinine \> twice the normal levels)
* Increase in methemoglobin levels (\> 5 times the normal levels)
* History of recent stroke (\< 1 month) and priapism
* Pregnancy
* Allergy to L-arginine
* Use of sildenafil, calcium channel blockers, nitroglycerin or other nitrates

Primary outcomes:
measure: Tricuspid regurgitant jet velocity >2.5 m/s
timeFrame: 6 months
Secondary outcomes:
measure: Lactate dehydrogenase levels
timeFrame: 6 months
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
state: RS
Study officials:
References:
Clinical trial NCT01836419: The Clinical Efficacy of Laryngeal Mask Airway in Elderly Patients: Comparison With Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Minor Urologic Surgery
Lower Extremity Surgery
Keywords: classic laryngeal mask airway
elderly patients
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-04-19
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are some differences between elderly and young adult patients regarding the anatomy of upper airways. Elderly patients have larger upper airways than young adult patients at all pharyngeal levels as revealed by CT. Another study explained that there is a progressive descent of the larynx and epiglottis with aging, which lengthens the upper airway and possibly makes it more likely to collapse.

The aim of this study is to compare the clinical efficacy of laryngeal mask airway (LMA) in elderly patients with young adults. In this study, the investigators will measure the ease of insertion, success rate of insertion, the time of insertion, oropharyngeal leak pressure, gastric leak pressure, fiberoptic position and intraoperative complications of the classic LMA.


Eligibility criteria: Inclusion Criteria:

* Patients aged 20-40 and 65-85years
* ASA status 1-2
* Undergoing minor urologic surgery or lower extremity surgery
* Undergoing general anesthesia using classic LMA

Exclusion Criteria:

* Predicted difficult airway
* Increased risk of aspiration
* Gastroesophageal reflux
* Neuromuscular disease
* Significant acute or chronic lung disease

Primary outcomes:
measure: oropharyngeal leak pressure
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance hospital
Study officials:
References:
Clinical trial NCT04232319: Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors
Official title: Feasibility of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Breast Cancer
Sleep Hygiene
Keywords: Breast cancer, sleep, intervention
Sleep
Intervention
Self-management
Lead sponsor: University of Toledo
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The proposed research will assess the feasibility and preliminary effectiveness of a Sleep Hygiene Program for Breast Cancer Survivors. Participants will complete assessments related to sleep issues, participate in a Sleep Hygiene Program, and complete another assessment post-intervention.


Eligibility criteria: Inclusion Criteria:

1. diagnosed with breast cancer and not currently receiving active treatment in the form of chemotherapy or radiation therapy,
2. at least 18 years of age,
3. women
4. score \> 5 on the Pittsburgh Sleep Quality Index
5. Participant has a smartphone that operates on the Android or Apple platform
6. Participant is able to use the Ecological Momentary Assessment application in the morning
7. functional English fluency and literacy

Exclusion Criteria:

1. self-reported history of diagnosis of co-morbidities that have been associated with poor sleep and fatigue: chronic insomnia, chronic fatigue syndrome, unstable heart, lung, or neuromuscular disease, insulin-dependent diabetes, sleep apnea, chronic oral steroid therapy, and night-shift employment.
2. Currently taking a pharmacological sleep aide

Primary outcomes:
measure: Change in Sleep Quality (Pittsburgh Sleep Quality Index)
timeFrame: Baseline to 7 weeks
Secondary outcomes:
measure: Change in Ecological Momentary Assessment of Sleep Quality
timeFrame: Baseline to 7 weeks
measure: Change in Actigraphy-based measure of Sleep
timeFrame: Baseline to 7 weeks
measure: Change in knowledge of Sleep Hygiene Strategies (Sleep Hygiene Index)
timeFrame: Baseline to 7 weeks
measure: Change in Ecological Momentary Assessment of Sleep Quantity
timeFrame: Baseline to 7 weeks
Other outcomes:
Locations:
city: Toledo
country: United States
facility: University of Toledo
state: Ohio
Study officials:
affiliation: University of Toledo
name: Ketki D Raina, PhD, OTR/L
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01608919: Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
Official title: Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Venous Thromboembolism
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2012-05-31
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study plans to learn more about the role of 2 blood tests in predicting who might develop a blood clot in their arm or leg after major surgery. The investigators know that patients who have cancer and major surgery have a higher than normal risk of getting blood clots in the veins of their arms or legs. This can be very dangerous because the clot can move into your lungs.

Detailed description: Venous Thromboembolism (VTE) after cancer surgery hospitalization is the most common cause of death at 30 days after cancer surgery, and is a significant source of patient morbidity and health care cost. Pharmacoprophylaxis has proven efficacy in preventing post-discharge VTE in surgical cancer patients, but perceived risks and costs pose barriers to widespread adoption by clinicians. Risk stratification of this patient population is necessary to allow appropriate prescription of prophylaxis to the highest risk patients. Can the investigators develop a risk stratification model that includes a readily available laboratory test, the thromboelastogram with or without platelet mapping?

Eligibility criteria: Inclusion Criteria:

* subjects who are having primary, open resection surgery of gastrointestinal or bladder cancer

Exclusion Criteria:

* currently receiving anticoagulation therapy
* pregnant

Primary outcomes:
measure: Venous thromboembolism free survival after surgery for gastrointestinal or urologic cancer
timeFrame: 3 months post-discharge from hospital
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Hospital
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Sara Cheng, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: